SCHEMBL23933143

SCHEMBL23933143

Cc1ccc(S(=O)(=O)NN=CC2(NC(=O)OC(C)(C)C)COC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.45
MEN1 O00255 8/20 0.40
KMT2A Q03164 8/20 0.40
POLB P06746 3/20 0.40
RECQL P46063 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KDM4E B2RXH2 2/20 0.39
RRM1 P23921 1/20 0.38
HTT P42858 2/20 0.37
ALOX12 P18054 1/20 0.37
F2 P00734 1/20 0.37
PRSS1 P07477 1/20 0.37
PRSS2 P07478 1/20 0.37
PRSS3 P35030 1/20 0.37
MAPT P10636 5/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
GAA P10253 1/20 0.36
RBM39 Q14498 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29768851 0.86 ALDH1A1 (0.44) ALDH1A1MEN1KMT2APOLBRECQL
SCHEMBL23933120 0.86 ALDH1A1 (0.44) ALDH1A1MEN1KMT2APOLBRECQL
SCHEMBL29768872 0.81 ALDH1A1 (0.41) ALDH1A1MEN1KMT2APOLBRECQL
SCHEMBL26388343 0.81 ALDH1A1 (0.45) ALDH1A1MEN1KMT2APOLBRECQL
SCHEMBL29768880 0.79 ALDH1A1 (0.45) ALDH1A1MEN1KMT2APOLBRECQL
SCHEMBL26388246 0.79 ALDH1A1 (0.45) ALDH1A1MEN1KMT2APOLBRECQL
SCHEMBL23933142 0.73 ALDH1A1 (0.46) ALDH1A1MEN1KMT2APOLBRECQL
SCHEMBL23933141 0.73 ALDH1A1 (0.46) ALDH1A1MEN1KMT2APOLBRECQL
SCHEMBL23857038 0.71 MEN1 (0.38) ALDH1A1MEN1KMT2ACYP2C9CYP2C19
SCHEMBL29000381 0.71 RAB9A (0.33) ALDH1A1MEN1KMT2APOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4271387-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF Immunext, Inc. (US) 2023-11-08 EP disclosed
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT INC (US) 2023-10-05 US disclosed
EP-4136118-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF Immunext, Inc. (US) 2023-02-22 EP disclosed
WO-2022150637-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF IMMUNEXT, INC. (US) 2022-07-14 WO disclosed
WO-2021216913-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT, INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF CD47, CLTA, FCGR2A ALDH1A1 2153/4885MEN1 2750/4885KMT2A 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.